### 1 SARS-CoV-2 Infection Breakthrough among the non-vaccinated and vaccinated: a Real

- 2 World Evidence study based on Big Data
- 3 Perrella  $A^{*1,6}$ , Bisogno  $M^3$ , D'Argenzio<sup>1,2</sup>, Trama  $U^{1,2}$ , Coscioni  $E^{1,4}$ , Orlando  $V^{*2,5}$
- 4 and COVID CaRe group
- <sup>1</sup> Regional Task Force COVID-19, Campania Region, Naples, Italy;
- 6 <sup>2</sup>Directorate-General for Health Protection, Campania Region, Naples, Italy;
- <sup>3</sup> Sinfonia Regional Health Information System of Campania Region, Naples, Italy;
- <sup>4</sup> Division of Cardiac Surgery, AOU San Giovanni di Dio e Ruggi d'Aragona, Salerno, Italy;
- 9 <sup>5</sup> CIRFF (Center of Drug Utilization and Pharmacoeconomics), Department of Pharmacy, University of Naples
- 10 Federico II, Naples, Italy;
- <sup>6</sup> Hospital Health Direction, Infectious Disease Unit, Hospital A. Cardarelli, Naples, Italy
- 12 \*Correspondence:
- 13 Valentina Orlando, email: <u>valentina.orlando@unina.it;</u>
- 14 Alessandro Perrella, email: <u>alessandro.perrella@aocardarelli.it</u>
- 15 Ethical Committee Waived: Prot.N. 00000926 11/01/2022

## 16 Collaborative Authors

17 The list of collaborators of the group and their affiliation are the following:

# 18 The COVID CaRe Group

Italo Giulivo<sup>1</sup>, Antonio Postiglione<sup>1,2</sup>, Claudia Campobasso<sup>1</sup>, Giuseppe Galano<sup>1</sup>, Maurizio Di 19 Mauro<sup>1</sup>, Enrico Coscioni<sup>1,5</sup>, Alessandro Perrella<sup>1,6</sup>, Angelo D'Argenzio<sup>1,2</sup>, Ugo Trama<sup>1, 2</sup>, Maria 20 Rosaria Romano<sup>1, 2</sup>, Giuseppina Tommasielli<sup>1</sup>, Ciro Verdoliva<sup>1</sup>, Antonio D'Amore<sup>1</sup>, Gennaro 21 Sosto<sup>1</sup>, Ferdinando Russo<sup>1</sup>, Maria Morgante<sup>1</sup>, Gennaro Volpe<sup>1</sup>, Mario Iervolino<sup>1</sup>, Carlo Marino<sup>1</sup>, 22 Paolo Russo<sup>1</sup>, Roberta Santaniello<sup>1</sup>, Michele Cioffi<sup>1</sup>, Guido Maria Talarico<sup>1</sup>, Giuseppe Longo<sup>1</sup>, 23 Mario Nicola Vittorio Ferrante<sup>1</sup>, Anna Iervolino<sup>1</sup>, Antonio Giordano<sup>1</sup>, Renato Pizzuti<sup>1</sup>, Vincenzo 24 25 D'Amato<sup>1</sup>, Antonio Limone<sup>1</sup>, Antonio Corcione<sup>1</sup>, Francesco Diurno<sup>1</sup>, Gaetano Gubitosa<sup>1</sup>, Pietro Buono<sup>2</sup>, Massimo Bisogno<sup>3</sup>, Valerio Morfino<sup>3</sup>, Valentina Orlando<sup>2,4</sup>, Enrica Menditto<sup>4</sup>, Ilaria 26 27 Guarino<sup>4</sup>, Francesca Futura Bernardi<sup>2</sup>, Giovanna Affinito<sup>2</sup>, Massimo Majolo<sup>6</sup>, Novella Carannante<sup>2</sup>. 28

- 29 <sup>1</sup> Regional crisis Unit COVID-19, Campania Region, Naples, Italy;
- <sup>2</sup> Directorate-General for Health Protection, Campania Region, Naples, Italy;
- 31 <sup>3</sup> Sinfonia Regional Health Information System of Campania Region, Naples, Italy
- 32 <sup>4</sup> CIRFF (Center of Drug Utilization and Pharmacoeconomics), Department of Pharmacy, University of Naples
- 33 Federico II, Naples, Italy;
- <sup>5</sup> Division of Cardiac Surgery, AOU San Giovanni di Dio e Ruggi d'Aragona, Salerno, Italy;
- <sup>6</sup> Hospital Health Direction, Infectious Disease Unit, Hospital A. Cardarelli, Naples, Italy

#### 36 ABSTRACT

- 37 Background:
- 38 SARS-CoV-2 infection after vaccination can occur because COVID-19 vaccines do not offer 100%
- 39 protection. The aim of this study was to assess vaccination coverage among people nasopharyngeal
- 40 swabs, disease symptoms and type of hospitalisation (Intensive Care Unit) between the non-
- 41 vaccinated and the effective dose vaccinated and to evaluate vaccination trend over time.

## 42 Methods:

- 43 A retrospective cohort study was carried out among people tested positive for COVID-19 in
- 44 Campania Region using collected information from Health Information System of Campania
- 45 Region (Sinfonia).
- 46 The status of vaccination was assess according to the following timetable: "non-vaccinated";
- 47 "Ineffective dose" vaccination; "Effective dose" vaccination.
- 48 Univariate and multivariate logistic regression models were conducted to evaluate the association
- 49 between Intensive Care Unit (ICU) to COVID-19 and gender, age groups and vaccine.
- 50 To determine vaccine coverage in subjects who received an effective dose, trend changes over time
- 51 were investigated using segmented linear regression models and breakpoints estimations.
- 52 Vaccination coverage was assessed by analysing the trend in the percentage of covid 19 positive
- subjects in the 9 months after vaccination with an effective dose stratified by age group and type of
- 54 vaccine. Statistical analyses were performed using R platform

# 55 **Results:**

- A significant association with the risk of hospitalisation in Intensive Care Unit was the vaccination status of the subjects: subjects with ineffective dose (adjusted OR: 3.68) and subjects novaccination (adjusted OR: 7.14) were at three- and seven-times higher risk of hospitalisation in Intensive Care Unit, respectively, than subjects with an effective dose.
- 60 Regarding subjects with an effective dose of vaccine, the vaccine's ability to protect against
- 61 infection in the months following vaccination decreased.
- 62 The first breakpoints is evident five months after vaccination ( $\beta = 1.441$ , p<0.001). This increase
- 63 was most evident after the seventh month after vaccination ( $\beta = 3.110$ , p<0.001).

# 64 **Conclusions:**

65 COVID19 vaccines protect from symptomatic infection by significantly reducing the risk of ICU 66 hospitalization for severe disease. However, it seems they have trend to decrease their fully 67 protection against SARS-COV-2 after five months regardless age, sex or type of vaccine. Therefore 68 it seems clear that those not undergoing vaccine had higher risk to develop clinically significant 69 disease and being at risk of ICU stay. Thus, considering highest percentage of asymptomatic

- 70 patients and that few data about their capacity to transmit SARS-CoV-2, third dose vaccination
- should be introduced as soon as possible while awaiting antivirals. Finally, a surveillance approach
- based on the use of integrated BIG Data system to match all clinical conditions too, offer a precise
- and real analysis with low incidence of errors in the categorization of subjects.
- 74 Keywords: COVID-19, vaccination coverage, Real World Evidence study, Big Data, Machine
- 75 Learning, SARS-COV-2, Vaccine.

## 76 Introduction

- 577 Since WHO declared the emergence of coronavirus disease 2019 (COVID-19) pandemic on March
- 11, 2020, over 5 million people have died worldwide, including over 130,000 people in Italy.<sup>1</sup>
- 79 Due to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection impact on health
- system of all countries, some countries or pharmaceutical companies have promoted research
   protocol to find a cure or to develop a vaccine against the SARS-CoV-2.<sup>2-4</sup>
- protocor to find a care of to develop a vacenie against are printed cor 2.
- 82 Currently several vaccines have been produced and authorized, being based on different
- technologies. In Italy at the end of 2020 and throughout 2021, following European Medical Agency
- 84 (EMA), Italian Medicines and Healthcare products Regulatory Agency (AIFA) authorized the
- 85 BNT162b2 mRNA (Pfizer-BioNTech) and ChAdOx1 nCoV-19 adenoviral (Oxford-AstraZeneca),
- 86 CX-024414 mRNA (Moderna) and Ad26.COV2-S Adenoviral (J&J). Since the authorization of
- 87 vaccine, thanks to extraordinary effort of all Italian healthcare workers and sense of civil
- responsibility of Italian population a high percentage of people were vaccinated and COVID19
- 89 contagious progressively decrease over the entire country during the first 8 months of 2021.<sup>5</sup>
- 90 Despite recent studies  $^{6-8}$  there is still a lack of studies on vaccine efficacy based on real world data.
- 91 The aim of this study was to assess vaccination coverage among people nasopharyngeal swabs,
- 92 disease symptoms and type of hospitalisation (Intensive Care Unit) between the non-vaccinated and
- 93 the effective dose vaccinated and to evaluate vaccination trend over time.

#### 94 Materials and Methods

# 95 Data sources: Sinfonia

- 96 Sinfonia includes records on patient demographics and for ~ 6 million residents, comprising a well-
- 97 defined population in Italy (~ 10% of the population of Italy).
- 98 Sinfonia collects information, encrypted and anonymized from Local Health Unit (LHU) whose are
- 99 legal owner of the original data, in accordance with the privacy laws. All analyses on the data are
- 100 therefore carried out on encrypted and anonymized data using transparent data encryption protocols.
- 101 It is complete and involves data management system that has been validated in previous studies. <sup>9-12</sup>
- 102 During the pandemic emergency, the Regional Health Information System of Campania Region
- 103 (Sinfonia) was implemented with all records related to COVID-19 in order to create a tool to
- 104 support health governance in managing the COVID-19 emergency.
- 105 The aims of Sinfonia tool, based on previous experiences too<sup>13</sup>, were:
- 106 1) Applying data science methods to big data in order to assess pandemic trends
- 107 2) Creation of predictive algorithms through AI methods
- ML analysis, performed according to the python scripting model (Spyder IDE 64bit ver), to
   perform predictive analysis on contagiousness.
- 110 The characteristics of Sinfonia are described in Supplementary Material 1

## 111 Study design and cohort selection

A retrospective cohort study was carried out among people tested positive for COVID-19 in
Campania Region since March 8, 2021, until 31 October 2021 using collected information from
Health Information System of Campania Region (Sinfonia).

- 115 Nasopharyngeal swabs were collected by trained personnel of Regional Healthcare system and/or 116 authorized and trained territorial laboratory staff. RT-PCR testing was performed with the use of
- 117 standardized RT-PCR machine from Coronavirus Network Laboratory (CoroNetLab), with four
- 118 genes analysis RdRP, S and N genes specific to SARS-CoV-2, and the E gene with results
- 119 expressed as the cycle threshold (Ct). A Ct value of less than 30, which indicated an increased viral
- 120 load, was used to determine infectivity.<sup>14,15</sup>
- 121 Were considered as fully positive only results when all 4 genes found to be amplified by Rt-PCR
- 122 while in all other case results were considered doubt and repeated. <sup>14,15</sup> Participant consent was
- 123 given for the release of all SARS-CoV-2 PCR test results before or after vaccination. All positive
- 124 participants were followed-up until negative PCR test.
- 125 For all individuals being positive at nasal swab clinical symptoms were collected according to
- 126 Italian National Health Institute. Typical COVID-19 symptoms were fever, cough, or change or loss
- 127 of taste or smell. Participants were recorded as having other symptoms if they reported any of the

following: shortness of breath, sore throat, runny nose, headache, muscle aches, extreme fatigue, diarrhoea, nausea or vomiting, or small itchy red patches on fingers or toes, on the follow-up questionnaire with a symptom onset date within 14 days before or after the PCR positive sample date.

132 Data extraction was conducted from Sinfonia every month to have e regular report of 133 vaccine/positive trend and for final analysis on October 31, 2021. All collected data after ML 134 algorithm were anonymized and encrypted according to transparent data encryption.

Briefly, AI based on ML algorithm, was used in data mining on Sinfonia to daily match records from SARS-COV-2 RT-PCR nasal swab and status of vaccination according to the following timetable:

138 i) Positive without vaccinated being considered "non-vaccinated"

139 ii) positive after 1<sup>st</sup> dose vaccine (<15 or >15 days) or after two dose vaccine < 15 days and</li>
140 being considered "*Ineffective dose*" vaccination,

141 iii) positive after two dose with more than 15 days since second dose of BNT162b2 mRNA

142 (Pfizer-BioNTech), ChAdOx1 nCoV-19 adenoviral (AstraZeneca) and CX-024414 mRNA

143 (Moderna) or in case of Ad26.COV2-S Adenoviral (J&J) 60 days after one shot and being
 144 considered "Effective dose" vaccination.

145 Flow chart is illustrated in Figure 1.

All subjects provided written informed consent to vaccination and data storage on a Big Data
system management to collect all COVID-19 patients' data and related clinical history (Symptoms,

148 hospital admission and related follow-up, previous clinical status) according to European Privacy

149 Policy to manage pandemic.

150 Time elapsed from second dose and onset of COVID-19 was calculated for all individuals to

151 evaluate risk of infection in time dependent way. Further, once recognized a positive subject among

152 those vaccinated was evaluated according to days elapsed since vaccine.

## 153 **Outcomes**

154 The primary outcome was to assess the risk of intensive care unit (ICU) admission for COVID-19

155 between the non-vaccinated and the effective dose vaccinated.

156 Secondary outcome was to evaluate vaccination coverage, over time, stratified by age group and

157 vaccine type

# 158 Statistical analysis

159 The study population baseline characteristics were analyzed using descriptive statistics.

160 Quantitative variables were described as counts and percentages. The chi-square test and t-test were

161 performed to determine the difference between non-vaccinated and vaccinated subjects who tested

- 162 positive for COVID-19. In particular, the vaccinated subjects were distinguished into two groups:
- 163 vaccinated with an ineffective dose (one vaccine dose or two vaccine doses) and vaccinated with an
- 164 effective dose (two vaccine doses plus 15 days: BNT162b2 mRNA (Pfizer-BioNTech), ChAdOx1
- 165 nCoV-19 adenoviral (AstraZeneca) and CX-024414 mRNA (Moderna); one vaccine dose plus 60
- 166 days: Ad26.COV2-S Adenoviral (J&J)).
- 167 Univariate and multivariate logistic regression models were conducted to evaluate the association
- 168 between Intensive Care Unit (ICU) to COVID-19 and gender, age groups (ie, 40 59 years, 60 79
- 169 years,  $\geq$  80 years vs 0-39 years) and vaccine (Non-vaccination, Ineffective dose vs Effective dose).
- 170 To determine vaccine coverage in subjects who received an effective dose, trend changes over time
- 171 were investigated using segmented linear regression models and breakpoints estimations.
- 172 Breakpoints were identified testing differences in slope and intercepts of the trend and then different
- 173 linear models were implemented. Changes in the slope segment indicated an impact of vaccination
- 174 coverage on protection against COVID-19 infection.
- 175 Every linear model was expressed as follows: yt = a + b \* t + et, where a was the intercept, b the
- 176 slope and et the error term. Coefficients ( $\beta$ ) were considered statistically significant with a P value <
- 177 0.05. The 95% confidence intervals (CIs) for each breakpoint were also obtained.
- 178 In addition, vaccination coverage was assessed by analysing the trend in the percentage of covid 19
- 179 positive subjects in the 9 months after vaccination with an effective dose stratified by age group and
- 180 type of vaccine. Statistical analyses were performed using R platform (version 3.6, The R
- 181 Formulation for Statistical Computing, Vienna, Austria).

# 182 **Results**

- 183 During analysed period 8 March 2021 to 31 October 2021, in Campania Region, 2,555,678 nasal
- 184 swabs were performed in subjects aged 18-98 years. Are showed in figure 1 of the total cohort of
- 185 COVID-19 positive subjects, 85.2% were non-vaccinated (N= 146.529) and 14.8% (N= 25.392)
- 186 were vaccinated. Of the 25,392 subjects who received at least one dose of vaccine, 7.5% (N=
- 187 12,906) received an ineffective dose; in comparison 7.3% (N=12,486) received an effective dose.
- 188 Of the total 171,921 COVID-19 positive subjects, 51.2% were females.
- 189 The analysis stratified by age group showed that among the total cohort of COVID-19 positive
- 190 subjects, 50.9% were aged 0 -39 years, 29.4% 40 59 years, 16.3% 60 79 years and 3.4% were
- 191 aged more than 80 years.
- Information of disease symptoms was not available for 34,119 subjects (19.8%) included in theanalysis.
- 194 In particular, the percentage of subjects with severe and critical COVID-19 decreased in the cohort
- of vaccinated subjects compared to non-vaccinated subjects. Among a total of 482 subjects with severe symptoms 89.4% of the subjects are non-vaccinated, 7.5% of the subjects are vaccinated with a non-effective dose and 3.1% of the subjects are vaccinated with an effective dose.
- Similarly, out of 57 subjects with critical symptoms 82.5% of the subjects are non-vaccinated,
  10.5% of the subjects are vaccinated with a non-effective dose and 7.0% of the subjects are
  vaccinated with an effective dose.
- Overall, 2.7% of the COVID-19 positive subjects were hospitalised and 0.1% were in intensive careunit.
- Among hospitalised subjects the majority (83.7%) were non-vaccinated, 10.3% received a noneffective dose and 6.0%) received an effective dose.
- Among subjects in Intensive Care Unit (ICU) the majority (90.5%) were non-vaccinated, 7.6% received a non-effective dose and 1.9% received an effective dose (Table 1).
- 207 Table 2 reports the results of the univariate and multivariate logistic regression analyses, which
- 208 showed that three independent variables made a statistically significant contribution to the model:
- 209 gender, age, and vaccination status of the subjects were the main determinants of the risk of 210 hospitalisation in Intensive Care Unit (ICU) to COVID-19.
- 211 A significant association with the risk of hospitalisation in Intensive Care Unit was the gender.
- 212 Males (adjusted odds ratio [OR]: 1.70; 95% CI: 1.29 2.24, p value <0.001) were at almost two
- 213 times higher risk of hospitalization in Intensive Care Unit than females. Similarly, a strong
- significant association with the risk of hospitalisation in Intensive Care Unit was the age. Subjects
- 215 aged 60-79 years (adjusted odds ratio [OR]: 33.53; 95% CI: 19.31-58.23, p value <0.001) and

216 subjects aged more than 80 years (adjusted odds ratio [OR]: 29.04; 95% CI: 14.48 - 58.27, p value 217 <0.001) were more than thirty times and twenty-nine times, respectively, likely to the risk of 218 hospitalization in Intensive Care Unit compared to subjects aged 0-39 years. Equivalent results were 219 found for the vaccination status of the subjects: subjects with ineffective dose (adjusted OR: 3.68; 220 95% CI: 1.23 - 11.02, p value <0.001) and subjects no-vaccination (adjusted OR: 7.14; 95% CI: 221 2.64 - 19.27, p value <0.001) were at three- and seven-times higher risk of hospitalisation in 222 Intensive Care Unit, respectively, than subjects with an effective dose. 223 In Campania region, from 8 March 2021 to 31 October 2021, 3.699.683 subjects received a

225 In Campania region, non o Match 2021 to 51 October 2021, 5.093.005 subjects received a
 224 complete vaccine schedule. Of all those vaccinated with effective dose 12,486 developed COVID 225 19, so the prevalence of COVID-19 positive vaccinated subjects was 0.33%.

Regarding 12,486 subjects with an effective dose of vaccine, the ability of the vaccine to protect against infection in the months following vaccination has been was investigated through the estimation of breakpoints, i.e., points in which data show deviations from stability in the background trend. Indeed, figure 2 shows the trend for the percentage of subjects testing positive for COVID-19 over the 9 months after an effective dose. Two breakpoints were identified from the analysis. The first breakpoints is evident five months after vaccination ( $\beta = 1.441$ , p<0.001). This increase was most evident after the seventh month after vaccination ( $\beta = 3.110$ , p<0.001).

The analysis stratified by age group showed a similar trend in subjects aged 0-39 years, 40-59 years and 60-79 years in terms of increased number of COVID-19 positive patients (about 50%) up to the sixth month after vaccination. On the contrary, among subjects aged over 80 years, the trend up to the sixth month after vaccination was different: the percentage of positive subjects did not exceed 40%.

238 On the other hand, six months after vaccination, the trend was similar in all age groups (figure 3).

The analysis stratified by vaccine type, however, showed that all subjects vaccinated with Ad26.COV2-S Adenoviral (J&J) (n=357) were positive for COVID-19 within one month after the effective dose (third month).

On the other hand, 50% of the subjects vaccinated with ChAdOx1 nCoV-19 adenoviral (AstraZeneca) (n=1,964) became positive from the fourth month after vaccination until they were all positive by the sixth month after vaccination. 50% of the subjects vaccinated with CX-024414 mRNA (Moderna) (n=785) became positive from the fourth month after vaccination, between the fourth and sixth month the trend remained constant, and then increased to 90% in the eighth month after vaccination.

- 248 37% of the subjects vaccinated BNT162b2 mRNA vaccine (Pfizer-BioNTech) (n=9,237) became
- 249 positive from the fourth month after vaccination, between the fourth and fifth month the trend
- 250 remained constant, and then increased to 67% in the eighth month after vaccination.


# 251 Discussion and Conclusion


Vaccines have been a really successful technology for controlling infectious diseases in the past. 252 253 COVID19 represented a never experienced global emergency with world wide spread and high 254 mortality rate and therefore vaccines have represented a possible solution to stop SARS-CoV-2 255 spreading. Indeed, since the early phase of vaccine campaign the COVID19 contagiousness have 256 registered a decrease<sup>5</sup>, however few real-world studies are available on prolonged follow-up and on 257 larger cohort population. As first consideration, according to our primary outcome, the results of 258 this large community study based on Campania Region population (ISTAT censed citizens at 259 December 2020 of 5.889.567) showed that vaccination with two doses of BNT162b2 or ChAdOx1 260 still significantly reduces the risk of new PCR-positive SARS-CoV-2 infection.

261 Further it is interestingly to emphasize that they also showed a strongly significant reduction of ICU 262 hospital stay when vaccinated patients are hospitalized compared to unvaccinated subjects (Table 263 2). However, despite these findings, we found a rate of breakthrough infection of (7.3%) among 264 studied population receiving an effective vaccination schedule while 0.33% of total vaccinated population in Campania Region. These showed increasing spread of positive RT-PCR according to 265 266 time elapsed from second dose vaccination with highest risk after five months while only after two 267 months for a single shot vaccine. The highest percentage of infected positive subjects were 268 asymptomatic while the dynamic of protection varied by vaccine type, with initially similar 269 effectiveness of both mRNA vaccines and ChAdOx1, that after 4 months become less effective 270 with a more rapid declining of coverage for adenoviral vector-based vaccine.

271 Concerning Ad26.COV2-S vaccine it seems to show a waning of adequate coverage after one 272 month after completing vaccination schedule. Those findings, however, demonstrated that vaccines 273 are able to decrease severity of SARS-CoV-2 disease once infected. Nonetheless, it seems also clear 274 that vaccine, even if effective to decrease severity of disease and risk of severe hospitalization, 275 showed a decrease in their efficacy to protect against SARS-CoV-2 contagiousness throughout the 276 time in a significant percentage but not the majority of vaccinated people. This consideration would 277 suggest that at least in some cases, the vaccine protected against symptomatic disease but not 278 against infection throughout the time. The possible reasons of our findings could be viral and 279 immune related. In fact it is to underline that according to data available for Italian National Institute of Health, in Italy and therefore in Campania we have had an increase in frequency of 280 Delta variant reaching at the end of July almost 95% of all isolated virus<sup>16</sup>. Thus a less effective 281 282 vaccine coverage when delta variant become dominant while vaccine campaign proceed could have 283 had a role in this breakthrough. Another explanation could be in different effects of vaccination on 284 immunity, cellular or humoral possibly determining different infective state<sup>17</sup> mainly characterized

285 by asymptomatic subjects. These considerations would also underline the need to better understand 286 what kind of impact asymptomatic infected vaccinated people may have on SARS-CoV-2 spreading 287 among unvaccinated and vaccinated people too. Indeed, even if the current findings of vaccine 288 effectiveness to protect against severe outcomes would seem to suggest that virus transmission and 289 nasopharyngeal viral presence may have limited consequences, we could have some important 290 consequences over time. In fact, in absence of an universal vaccination possible environments 291 where the SARS-CoV-2 may develop elusive strategies by increasing its mutational rate or fitness 292 could compromise vaccine efficacy. The latter event could make herd immunity less likely with 293 possible severe evolution in particular settings of patients. Despite this could be possible future 294 scenario, our findings may be of usefulness in preventing it. Particularly our study has two main 295 strengths. First, we provide extensive documentation on a large cohort of breakthrough infections, 296 based on a Regional Big Data where all COVID19 positive data are automatically evaluated, 297 matched and analysed for their vaccine status by real time ML algorithm, minimizing error on 298 records giving a real time scenario and trend. Second, this cohort is one of the largest presented in 299 literature and represents all ages underwent vaccination with a very good representation of all 300 currently approved vaccines. Therefore, in conclusion, in this study we found that although the 301 current approved COVID19 vaccine are extremely effective in reducing hospitalization and particularly ICU, breakthrough infections occur with a breakpoint between 5<sup>th</sup> and 7<sup>th</sup> month after 302 303 vaccination and they may carry a potential infectiveness. This event could represent a challenge, 304 since such infections are often asymptomatic and may pose a risk to vulnerable populations. Consequently, a boost dose could be a possible strategy while awaiting the antiviral <sup>18, 19</sup> that could 305 306 give us a final weapon against SARS-CoV-2. However, considering highest percentage of 307 asymptomatic patients and that few data about their capacity to transmit SARS-CoV-2, further 308 screening, quarantine procedure and other preventing strategies should be guaranteed in all 309 vaccinated subjects. Finally, a surveillance approach based on the use of integrated BIG Data 310 system to match all clinical conditions too, offer a precise and real analysis with low incidence of 311 errors in the categorization of subjects.





314

\*Effective dose: two vaccine doses plus 15 days (ChAdOx1-S AstraZeneca, CX-024414 Moderna, BNT162b2 BioNTech/Pfizer); one vaccine dose plus 60 days (Ad26.COV2-S J&J)

#### 315 Table 1. General characteristics of COVID-19 positive patients

			Vaccinat		
	Total N (%)	No	Ineffective dose		
			1 <sup>st</sup> dose	2 <sup>nd</sup> doses	Effective dose*
	171,921 (100)	146,529 (85.2)	10,772 (6.3)	2,134 (1.2)	12,486 (7.3)
Gender					
Male	83,924 (48.8)	71,693 (85.4)	5,249 (6.3)	1,168 (1.4)	5,814 (6.9)
Female	87,997 (51.2)	74,836 (85.0)	5,523 (6.3)	966 (1.1)	6,672 (7.6)
Age Groups					
0 - 39 years	87,464 (50.9)	79,686 (91.1)	3,101 (3.5)	1,099 (1.3)	3,578 (4.1)
40 - 59 years	50,539 (29.4)	42,042 (83.2)	3,419 (6.8)	462 (0.9)	4,616 (9.1)
60 - 79 years	28,079 (16.3)	21,331 (76.0)	3,371 (12.0)	372 (1.3)	3,005 (10.7)
$\geq 80$ years	5,839 (3.4)	3,470 (59.4)	881 (15.1)	201 (3.4)	1,287 (22.0)
Vaccine type					
ChAdOx1-S (AstraZeneca)	6,067 (3.5)	-	3,913 (64.5)	190 (3.1)	1,964 (32.4)
Ad26.COV2-S (J&J)	1,181 (0.7)	_	824 (69.8)	_	357 (30.2)
CX-024414 (Moderna)	1,774 (1.0)	_	898 (50.6)	91 (5.1)	785 (44.3)
BNT162b2 (Pfizer-BioNTech)	15,657 (9.1)	_	5,422 (34.6)	998 (6.4)	9,237 (59.0)
Disease Symptoms					
Asymptomatic	112,251 (65.3)	95,482 (85.1)	7,343 (6.5)	1,526 (1.4)	7,900 (7.0)
Paucysinintomatic	14,339 (8.3)	12,542 (87.5)	865 (6.0)	134 (0.9)	798 (5.6)
Mild	10,673 (6.2)	9,368 (87.8)	599 (5.6)	60 (0.6)	646 (6.1)
Severe	482 (0.3)	431 (89.4)	35 (7.3)	1 (0.2)	15 (3.1)
Critical	57 (0.03)	47 (82.5)	6 (10.5)	-	4 (7.0)
Not available	34,119 (19.8)	28,659 (84.0)	1,924 (5.6)	413 (1.2)	3,123 (9.2)
Hospitalisation					
Yes	4705 (2.7)	3,939 (83.7)	431 (9.2)	52 (1.1)	283 (6.0)
No	167,216 (97.3)	142,590 (85.3)	10,341 (6.2)	2,082 (1.2)	12,203 (7.3)
Intensive Care Unit (ICU)					
Yes	211 (0.1)	191 (90.5)	16 (7.6)	-	4 (1.9)
No	171,710 (99.9)	146,338 (85.2)	10,756 (6.3)	2,134 (1.2)	12,482 (7.3)

316 317

) days (A <sup>#</sup>Uaccine type: only for subjects who have received at least one dose of vaccine *52);* ( se plus *s*)

318 Table 2. Univariate and multivariate logistics regression of the risk of hospitalisation in Intensive Care Unit (ICU) to


319 COVID-19


COVID-19				
	Unadjusted OR (95% CI)	p-Value	Adjusted OR (95% CI)	p-Value
Gender				
Male (vs Female)	1.59 (1.20 - 2.09)	0.001*	1.70 (1.29 - 2.24)	< 0.001*
Age groups				
40 - 59 years (vs 0-39 years)	5.57 (3.05 - 10.14)	< 0.001*	5.99 (3.28 - 10.90)	<0.001*
60 - 79 years (vs 0-39 years)	29.73 (17.13 - 51.57)	< 0.001*	33.53 (19.31 - 58.23)	<0.001*
$\geq$ 80 years (vs 0–39 years)	20.39 (10.21 - 40.69)	< 0.001*	29.04 (14.48 - 58.27)	<0.001*
Vaccination				
Ineffective dose (vs Effective dose)	3.94 (1.31 - 11.79)	0.014*	3.68 (1.23 - 11.02)	0.020*
No-vaccination (vs Effective dose)	4.11 (1.52 - 11.06)	0.005*	7.14 (2.64 - 19.27)	< 0.001*


Abbreviations: CI, confidence interval; OR, odds ratio


320 321 \*p-value < 0.05 was considered to be statistically significant.














# 331 **References**

- WHO Coronavirus (COVID-19) Dashboard. <u>https://covid19.who.int/</u> Accessed on 1 November
   2021
- Krammer F. SARS-CoV-2 vaccines in development. Nature. 2020 Oct;586(7830):516-527. doi:
   10.1038/s41586-020-2798-3. Epub 2020 Sep 23.
- 336 3. Optimising the COVID-19 vaccination programme for maximum short-term impact.
   337 <u>https://www.gov.uk/government/publications/prioritising-the-first-covid-19-vaccine-dose-jcvi-</u>
   338 <u>statement/optimising-the-covid-19-vaccination-programme-for-maximum-short-term-impact</u>
   339 Accessed on 1 November 2021
- Mallapaty S. Can COVID vaccines stop transmission? Scientists race to find answers. Nature.
   2021 Feb 19. doi: 10.1038/d41586-021-00450-z. Epub ahead of print.
- 342 5. Impatto della vaccinazione COVID-19 sul rischio di infezione da SARS-CoV-2 e successivo
   343 ricovero e decesso in Italia <u>https://www.epicentro.iss.it/vaccini/pdf/report-valutazione-impatto-</u>
   344 <u>vaccinazione-covid-19-15-mag-2021.pdf</u> Accessed on 1 November 2021
- Bergwerk M, Gonen T, Lustig Y, Amit S, Lipsitch M, Cohen C, Mandelboim M, Levin EG,
   Rubin C, Indenbaum V, Tal I, Zavitan M, Zuckerman N, Bar-Chaim A, Kreiss Y, Regev-Yochay
   G. Covid-19 Breakthrough Infections in Vaccinated Health Care Workers. N Engl J Med. 2021
   Oct 14;385(16):1474-1484. doi: 10.1056/NEJMoa2109072. Epub 2021 Jul 28
- 349 7. Khoury J, Najjar-Debbiny R, Hanna A, Jabbour A, Abu Ahmad Y, Saffuri A, Abu-Sinni M,
  350 Shkeiri R, Elemy A, Hakim F. COVID-19 vaccine Long term immune decline and
  351 breakthrough infections. Vaccine. 2021 Nov 26;39(48):6984-6989. doi:
  352 10.1016/j.vaccine.2021.10.038. Epub 2021 Oct 30.
- Pouwels KB, Pritchard E, Matthews PC, Stoesser N, Eyre DW, Vihta KD, House T, Hay J, Bell
   JI, Newton JN, Farrar J, Crook D, Cook D, Rourke E, Studley R, Peto TEA, Diamond I, Walker
   AS. Effect of Delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2
   infections in the UK. Nat Med. 2021 Oct 14. doi: 10.1038/s41591-021-01548-7. Epub ahead of
   print.
- 9. Perrella A, Orlando V, Trama U, Bernardi FF, Menditto E, Coscioni E. Pre-Exposure
  Prophylaxis with Hydroxychloroquine Does Not Prevent COVID-19 nor Virus Related Venous
  Thromboembolism. Viruses. 2021 Oct 13;13(10):2052. doi: 10.3390/v13102052.
- 361 10. Orlando V, Coscioni E, Guarino I, Mucherino S, Perrella A, Trama U, Limongelli G, Menditto
  362 E. Drug-utilisation profiles and COVID-19. Sci Rep. 2021 Apr 26;11(1):8913. doi:
  363 10.1038/s41598-021-88398-y.
- 364 11. Orlando V, Rea F, Savaré L, Guarino I, Mucherino S, Perrella A, Trama U, Coscioni E,
  365 Menditto E, Corrao G. Development and validation of a clinical risk score to predict the risk of
  366 SARS-CoV-2 infection from administrative data: A population-based cohort study from Italy.
  367 PLoS One. 2021 Jan 20;16(1):e0237202. doi: 10.1371/journal.pone.0237202.
- 368 12. Bliek-Bueno K, Mucherino S, Poblador-Plou B, González-Rubio F, Aza-Pascual-Salcedo M,
  369 Orlando V, (...) Gimeno-Miguel A. Baseline Drug Treatments as Indicators of Increased Risk of
  370 COVID-19 Mortality in Spain and ItalyInt. J Environ Res Public Health. 2021 Nov
  371 10;18(22):11786. doi: 10.3390/ijerph182211786

372 13. Perrella A, Carannante N, Berretta M, Rinaldi M, Maturo N, Rinaldi L. Novel Coronavirus 2019
373 (Sars-CoV2): a global emergency that needs new approaches? Eur Rev Med Pharmacol Sci.
374 2020 Feb;24(4):2162-2164.

- 375
- 376 14. Rhee C, Kanjilal S, Baker M, Klompas M. Duration of Severe Acute Respiratory Syndrome
  377 Coronavirus 2 (SARS-CoV-2) Infectivity: When Is It Safe to Discontinue Isolation? Clin Infect
  378 Dis. 2021 Apr 26;72(8):1467-1474. doi: 10.1093/cid/ciaa1249.
- 379 15. Perrella A, Brita M, Coletta F, Cotena S, De Marco G, Longobardi A, Sala C, Sannino D,
  380 Tomasello A, Perrella M, Russo G, Tarsitano M, Chetta M, Della Monica M, Orlando V,
  381 Coscioni E, Villani R. SARS-CoV-2 in Urine May Predict a Severe Evolution of COVID-19. J
  382 Clin Med. 2021 Sep 8;10(18):4061. doi: 10.3390/jcm10184061.
- 383 16. <u>https://www.iss.it/cov19-cosa-fa-iss-varianti/asset\_publisher/yJS4xO2fauqM/content/id/5807918</u>
- 384

Wei J, Stoesser N, Matthews PC, Ayoubkhani D, Studley R, Bell I, Bell JI, Newton JN, Farrar J,
Diamond I, Rourke E, Howarth A, Marsden BD, Hoosdally S, Jones EY, Stuart DI, Crook DW,
Peto TEA, Pouwels KB, Eyre DW, Walker AS; COVID-19 Infection Survey team. Antibody
responses to SARS-CoV-2 vaccines in 45,965 adults from the general population of the United
Kingdom. Nat Microbiol. 2021 Sep;6(9):1140-1149. doi: 10.1038/s41564-021-00947-3. Epub
2021 Jul 21.

18. Fischer W, Eron JJ, Holman W, Cohen MS, Fang L, Szewczyk LJ, Sheahan TP, Baric R, Mollan
KR, Wolfe CR, Duke ER, Azizad MM, Borroto-Esoda K, Wohl DA, Loftis AJ, Alabanza P,
Lipansky F, Painter WP. Molnupiravir, an Oral Antiviral Treatment for COVID-19. medRxiv
[Preprint]. 2021 Jun 17:2021.06.17.21258639. doi: 10.1101/2021.06.17.21258639.

395 19. Salasc F, Lahlali T, Laurent E, Rosa-Calatrava M, Pizzorno A. Treatments for COVID-19:
396 Lessons from 2020 and new therapeutic options [published online ahead of print, 2021 Nov 18].
397 Curr Opin Pharmacol. 2021;doi:10.1016/j.coph.2021.11.002)